THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS St Peter Port, Guernsey 30 June 2025 NB Private Equity Partners (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 12 June 2025 and the share buy-back agreement with Jefferies International Limited. Transaction on Lo ...

VANCOUVER, BC, June 30, 2025 (GLOBE NEWSWIRE) -- Digital Asset Technologies Inc. (CSE: DATT) (OTCPK: EATBF) (FSE: 988) (“DATT” or the “Company”), a technology focused investment issuer, is pleased to announce that its wholly owned portfolio company, LiquidLink AI Corp. (“LiquidLink”) has launched enterprise-grade infrastructure on the Bitcoin Lightning Network and Ripple’s Interledger Protocol (ILP). These deployments position LiquidLink as a foundational hub in the emerging Internet of Value, much like the ...

Core Viewpoint - Trifork Group has initiated a share buyback program to repurchase shares, which is expected to enhance shareholder value and provide flexibility in managing capital structure [1][2]. Group 1: Share Buyback Program Details - The share buyback program commenced on 4 March 2025 and will continue until 30 June 2025, with a total budget of DKK 14.92 million (approximately EUR 2 million) [1][2]. - As of the latest report, Trifork has repurchased a total of 131,824 shares for a total amount of DKK 11,780,821, with an average purchase price of DKK 89.37 [2]. - The company held 256,329 treasury shares prior to the buyback, which represented 1.3% of the share capital [2]. Group 2: Utilization of Repurchased Shares - Shares acquired through the buyback program have been utilized for executive management's monthly fixed salary and for the RSU plan, indicating a shift from cash payments to share-based compensation [3]. - Specifically, 5,739 shares were used for salary payments on four occasions, and 19,943 shares were allocated for the RSU plan on 1 April 2025 [3]. Group 3: Current Treasury Shares and Outstanding Shares - Following the buyback transactions, Trifork now holds a total of 363,840 treasury shares, which corresponds to 1.8% of the total registered shares [4]. - The total number of registered shares in Trifork is 19,744,899, leading to 19,381,059 outstanding shares after adjusting for treasury shares [4].

Map Cloche d'Or Map Cloche d'Or Eosys Building Cloche d'Or detail Eosys Building Cloche d'Or detail Eosys Building Cloche d'Or Eosys Building Cloche d'Or PRESS RELEASE NON REGLUATED INFORMATIONLuxembourg, 30 June 2025, 7:30 AM Nextensa, in collaboration with Promobe via their joint venture Grossfeld, launches the construction of Eosys, its new sustainable office building at Cloche d’Or Luxembourg, 30 June 2025 - Nextensa, in collaboration with Promobe via their joint venture Grossfeld, has conc ...

Press Release VALLOUREC SECURES A SIGNIFICANT OCTG ORDER WITH ABU DHABI NATIONAL OIL COMPANY (ADNOC) Meudon (France), June 30, 2025 – Vallourec, a world leader in premium seamless tubular solutions, has secured a significant order from Abu Dhabi National Oil Company (ADNOC) for the supply of more than 30,000 tons of carbon steel tubulars and associated accessories featuring VAM® premium connections. This order is part of the ongoing Long-Term Agreement (LTA) for the supply of Oil Country Tubular Goods (OCTG ...

Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to mid-September 2025 New Drug Application (NDA) submission in the U.S. targeted for H1 2026 June 30, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient has completed the Denali Phase 3 trial, evaluating the efficacy and safety of NCX 470, its lead comp ...

Availability of the Q2 2025 Aide mémoire Paris, France – June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: Second quarter 2025 (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's second quarter 2025 results will be ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. Stalicla will use the financing to advance its portfolio of autism focu ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatmentJapanese Ministry of Health, Labour and Welfare decision adds to similar designations in the US and Europe, underscoring global regulatory recognition of the potential for riliprupart to address significant unmet medical needs for people living with this rare neurological condition ...

Ad hoc announcement pursuant to Art. 53 LR Potential first-ever vaccine directed against C. difficile bacteria and spores induces positive antigen titers in humans that recognize the bacteriaInitial data from healthy participants confirm the vaccine is safe, well-tolerated and immunogenicThe study serves as a clinical validation for Idorsia's revolutionary synthetic glycan vaccine technologyIdorsia will now activate partnering discussions to advance as fast as possible the development of the C. difficile va ...